Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00216060 · ClinicalTrials.gov registry record · Phase 3
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase 3 study, sponsored by Christopher Sweeney, MBBS.
- Terminated
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT00216060: Clinical Trial Phase 3 study, sponsored by Christopher Sweeney, MBBS.
NCT00216060 is a Phase 3 study that was terminated before completion, run by Christopher Sweeney, MBBS. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00216060, a Phase 3 study, was terminated before completion, sponsored by Christopher Sweeney, MBBS.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
Risedronate is an orally administered pyridinyl bisphosphonate that is 36 times more potent than pamidronate and 72 times more potent than clodronate. Four randomized, double-blind trials have been carried out in patients with postmenopausal osteoporosis. In 2 of these studies, vertebral fracture incidence was reduced by a daily dose of 5 mg risedronate by up to 65% and 49% relative to placebo after 1 and 3 years, respectively. In these trials, risedronate improved lumbar spine, femoral neck, and femoral trochanter bone mineral density (BMD) at 6 months. In addition, preclinical studies have shown that risedronate is more potent than pamidronate and clodronate in inhibiting adhesion of prostate cancer cells to bone and preventing tumor cell invasion. The incidence of osteoporosis in prostate cancer patients has been well established; therefore, it is advantageous to assess the efficacy of oral bisphosphonate therapy.
Interventions
- DRUG Placebo
- DRUG Risedronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2003-10 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00216060
The ClinicalTrials.gov registry entry for NCT00216060 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Christopher Sweeney, MBBS, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00216060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00216060 about?
NCT00216060 is a clinical study titled "Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy". Risedronate is an orally administered pyridinyl bisphosphonate that is 36 times more potent than pamidronate and 72 times more potent than clodronate. Four randomized, double-blind trials have been carried out in patients with postmenopausal osteoporosis. In 2 of these studies, vertebral fracture in...
What is the current status of trial NCT00216060?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2003-10. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00216060?
The interventions under investigation include: Placebo (DRUG), Risedronate (DRUG).
Who is sponsoring clinical trial NCT00216060?
This trial is sponsored by Christopher Sweeney, MBBS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.